tiprankstipranks
Max Healthcare Institute Ltd (IN:MAXHEALTH)
:MAXHEALTH
India Market
Want to see IN:MAXHEALTH full AI Analyst Report?

Max Healthcare Institute Ltd (MAXHEALTH) AI Stock Analysis

8 Followers

Top Page

IN:MAXHEALTH

Max Healthcare Institute Ltd

(MAXHEALTH)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 5.2)
Rating:66Neutral
Price Target:
₹1,092.00
▼(-9.18% Downside)
Action:ReiteratedDate:11/01/25
Max Healthcare Institute Ltd shows strong financial performance with consistent revenue growth and profitability, which is a significant positive factor. However, the high P/E ratio and low dividend yield suggest the stock may be overvalued, impacting its attractiveness. Technical indicators show a lack of strong momentum, contributing to a moderate overall score.
Positive Factors
Revenue Growth
Sustained top-line growth near 24.4% indicates expanding patient volumes, improved utilization or pricing across the hospital network. Over the next 2–6 months this supports scale economics, capacity investments and revenue resilience versus peers in a capital-intensive sector.
Negative Factors
Rising Debt Trend
Although current leverage (D/E 0.32) is moderate, a rising total debt trend can reduce financial flexibility and increase interest exposure. If debt growth outpaces cash generation it could constrain funding for strategic projects and heighten refinancing risk over 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line growth near 24.4% indicates expanding patient volumes, improved utilization or pricing across the hospital network. Over the next 2–6 months this supports scale economics, capacity investments and revenue resilience versus peers in a capital-intensive sector.
Read all positive factors

Max Healthcare Institute Ltd (MAXHEALTH) vs. iShares MSCI India ETF (INDA)

Max Healthcare Institute Ltd Business Overview & Revenue Model

Company Description
Max Healthcare Institute Limited provides healthcare services in India. It offers services in various specialties, including cancer care/oncology, cardiac sciences, neuro sciences, liver transplant and biliary sciences, orthopaedics, nephrology, k...
How the Company Makes Money
Max Healthcare primarily makes money by delivering healthcare services to patients through its hospitals and associated centers. Its core revenue stream is patient care services, which typically include (i) inpatient services (room/bed charges, in...

Max Healthcare Institute Ltd Financial Statement Overview

Summary
Max Healthcare Institute Ltd exhibits a strong financial position with consistent revenue growth and profitability. The balance sheet remains stable with moderate leverage, and cash flow generation is robust. While the company shows promising financial health, careful attention to operating efficiency and debt levels will be crucial for sustaining long-term growth and stability.
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue79.41B70.28B54.06B45.63B39.37B25.08B
Gross Profit52.71B43.77B33.53B28.31B21.89B12.76B
EBITDA20.81B18.31B14.82B12.23B9.47B3.90B
Net Income13.57B10.76B10.58B11.04B6.05B-1.38B
Balance Sheet
Total Assets162.81B152.14B120.00B101.02B91.89B85.44B
Cash, Cash Equivalents and Short-Term Investments5.73B6.82B9.80B13.74B4.81B6.27B
Total Debt32.75B30.10B13.05B6.89B11.33B13.25B
Total Liabilities62.29B58.34B35.92B26.92B29.07B29.06B
Stockholders Equity100.52B93.81B84.08B74.10B62.82B56.39B
Cash Flow
Free Cash Flow-413.10M4.94B3.36B8.74B1.87B-5.60M
Operating Cash Flow8.18B14.59B11.22B12.09B7.48B1.18B
Investing Cash Flow-9.66B-16.32B-12.85B-11.87B-7.72B-730.00M
Financing Cash Flow-353.20M-1.64B-2.64B-2.89B-2.94B1.91B

Max Healthcare Institute Ltd Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1202.35
Price Trends
50DMA
1015.00
Negative
100DMA
1039.98
Negative
200DMA
1118.26
Negative
Market Momentum
MACD
-9.63
Negative
RSI
57.89
Neutral
STOCH
92.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MAXHEALTH, the sentiment is Neutral. The current price of 1202.35 is above the 20-day moving average (MA) of 963.87, above the 50-day MA of 1015.00, and above the 200-day MA of 1118.26, indicating a neutral trend. The MACD of -9.63 indicates Negative momentum. The RSI at 57.89 is Neutral, neither overbought nor oversold. The STOCH value of 92.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:MAXHEALTH.

Max Healthcare Institute Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
₹375.98B75.820.24%25.81%-0.76%
66
Neutral
₹988.47B84.460.14%24.44%40.69%
66
Neutral
₹1.12T50.390.27%14.52%37.54%
65
Neutral
₹317.64B83.790.04%17.16%1.24%
63
Neutral
₹378.80B61.580.84%12.20%-93.03%
61
Neutral
₹722.83B86.120.11%15.99%24.81%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,015.70
-134.37
-11.68%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
7,756.50
795.77
11.43%
IN:ASTERDM
Aster DM Healthcare Ltd.
731.10
196.84
36.84%
IN:FORTIS
Fortis Healthcare Ltd.
957.45
275.91
40.48%
IN:MEDANTA
Global Health Limited
1,181.45
-28.91
-2.39%
IN:NH
Narayana Hrudayalaya Ltd.
1,839.80
18.19
1.00%

Max Healthcare Institute Ltd Corporate Events

Max Healthcare Wins Full Withdrawal of ₹55.20 Crore GST Demand
Apr 21, 2026
Max Healthcare Institute Ltd has disclosed that the Delhi GST authority has issued a rectification order in its favour related to an earlier tax dispute over alleged excess availment of input tax credit. The order fully withdraws the previously ra...
Max Healthcare launches e-voting postal ballot for director re-appointment
Apr 12, 2026
Max Healthcare Institute Ltd has notified stock exchanges that it has published a postal ballot notice in national and regional newspapers and has completed dispatch of the notice to eligible shareholders via email. The move underscores the compan...
Max Healthcare reports no demat requests, confirms fully dematerialized share base
Apr 7, 2026
Max Healthcare Institute Ltd has disclosed that its registrar and share transfer agent, MUFG Intime India Private Limited, confirmed there were no requests for dematerialization of shares during the quarter ended March 31, 2026. The company also r...
Max Healthcare Closes Trading Window Ahead of FY26 Results
Mar 26, 2026
Max Healthcare Institute Ltd has announced the closure of its trading window for all designated persons and their immediate relatives from April 1, 2026, until 48 hours after the declaration of its financial results for the fourth quarter and full...
Max Healthcare Subsidiary ET Planners Dissolved After Voluntary Liquidation
Mar 25, 2026
Max Healthcare Institute Ltd has disclosed that its step-down wholly owned subsidiary, ET Planners Private Limited, has been dissolved following an order by the National Company Law Tribunal’s New Delhi Bench under the voluntary liquidation ...
Max Healthcare to Engage Investors at J.P. Morgan India Forum 2026 in Singapore
Mar 2, 2026
Max Healthcare Institute Ltd has announced that its Chairman and Managing Director will participate in the J. P. Morgan India Forum 2026, an investor conference to be held physically at the Fullerton Hotel in Singapore on March 9 and 10, 2026. The...
Max Healthcare Posts Audio Recording of Q3 FY26 Earnings Call Online
Feb 6, 2026
Max Healthcare Institute Limited has notified the stock exchanges that the audio recording of its earnings call held on February 6, 2026, discussing the company’s financial results for the quarter and nine months ended December 31, 2025, has...
Max Healthcare Publishes Unaudited Q3 and Nine-Month FY2025 Results
Feb 6, 2026
Max Healthcare Institute Limited has announced that its Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, at a meeting held on February 5, 2026. In line...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 01, 2025